Intravenous human immunoglobulin (pH4) (Sinopharm Guizhou Plasma)

静注人免疫球蛋白 (pH4)（国药贵州血液）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIntravenous human immunoglobulin (pH4) (Sinopharm Guizhou Plasma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > ImmunoglobulinBiologics > Blood components
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Global Approved IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Approved Indications in ChinaX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date2012/06/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSinopharm Group Guizhou Bio-pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinopharm Group Guizhou Bio-pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsX chain low immunoglobulinAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeJ06BA02
Related LinksN/A